Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

Hartmut Döhner, Michael Lübbert, Walter Fiedler, Loic Fouillard, Alf Haaland, Joseph M. Brandwein, Stephane Lepretre, Oumedaly Reman, Pascal Turlure, Oliver G. Ottmann, Carsten Müller-Tidow, Alwin Krämer, Emmanuel Raffoux, Konstanze Döhner, Richard F. Schlenk, Florian Voss, Tillmann Taube, Holger Fritsch, Johan Maertens

Blood (2014) 124 (9): 1426–1433.

https://doi.org/10.1182/blood-2014-03-560557

Published: 2014

Includes: Supplemental data

Journal Articles

Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment

Johan Maertens, MD, PhD, Michael Lübbert, MD, Walter Fiedler, MD, Loic Fouillard, Alf Haaland, MD, Joseph M. Brandwein, MD, Stéphane Lepretre, MD, Oumédaly Reman, MD, Pascal Turlure, MD, Gesine Bug, Carsten Müller-Tidow, Alwin Krämer, MD, Florian Voss, PhD, Tillmann Taube, MD, Holger Fritsch, PhD, Hartmut Döhner, MD

Blood (2012) 120 (21): 411.

https://doi.org/10.1182/blood.V120.21.411.411

Published: 2012

Journal Articles

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

Vivek L. Patel, Matthieu Mahévas, Soo Y. Lee, Roberto Stasi, Susanna Cunningham-Rundles, Bertrand Godeau, Julie Kanter, Ellis Neufeld, Tillmann Taube, Ugo Ramenghi, Shalini Shenoy, Mary J. Ward, Nino Mihatov, Vinay L. Patel, Philippe Bierling, Martin Lesser, Nichola Cooper, James B. Bussel

Blood (2012) 119 (25): 5989–5995.

https://doi.org/10.1182/blood-2011-11-393975

Published: 2012

Journal Articles

Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML

Gesine Bug, MD, Carsten Müller-Tidow, MD, Richard F Schlenk, MD, Alwin Krämer, MD, Michael Lübbert, MD, PhD, Utz Krug, MD, Florian Voss, PhD, Tillmann Taube, MD, Holger Fritsch, PhD, Pilar Garin-Chesa, MD, PhD, Oliver G Ottmann, MD, Hartmut Döhner, MD

Blood (2011) 118 (21): 1549.

https://doi.org/10.1182/blood.V118.21.1549.1549

Published: 2011

Journal Articles

Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP)

Vivek L. Patel, MS, Matthieu Mahévas, MD, Roberto Stasi, MD, Susanna Cunningham-Rundles, PhD, Bertrand Godeau, MD, Soo Y. Lee, BS, Julie Kanter, MD, Ellis J. Neufeld, MD, PhD, Tillmann Taube, MD, Ugo Ramenghi, MD, Shalini Shenoy, MD, Mary J. Ward, PhD, Nino Mihatov, BS, Vinay L. Patel, BS, Philippe Bierling, MD, Nichola Cooper, MD, James B. Bussel, MD

Blood (2010) 116 (21): 72.

https://doi.org/10.1182/blood.V116.21.72.72

Published: 2010

Journal Articles

Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Gesine Bug, MD, PhD, Richard F. Schlenk, MD, PhD, Carsten Müller-Tidow, MD, PhD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, PhD, Frank Fleischer, Tillmann Taube, MD, Oliver G. Ottmann, MD, PhD, Hartmut Doehner, MD, PhD

Blood (2010) 116 (21): 3316.

https://doi.org/10.1182/blood.V116.21.3316.3316

Published: 2010

Journal Articles

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

C. Müller-Tidow, MD, Gesine Bug, MD, Richard Schlenk, MD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, Juergen Krauter, MD, David Nachbaur, MD, Peter Valent, MD, Tillmann Taube, MD, Gerd Munzert, MD, Kang-Hun Lee, MD, Hartmut Dohner, MD

Blood (2008) 112 (11): 2973.

https://doi.org/10.1182/blood.V112.11.2973.2973

Published: 2008

Journal Articles

Specific Inhibition of BCR-ABL Gene Expression in Acute Lymphoblastic Leukemia by Catalytic DNAzymes.

Tillmann Taube, MD, Shabnam Shalapour, Georg J. Seifert, MD, Madlen Pfau, Guenter Henze, MD, PhD, Karlheinz Seeger, MD, PhD

Blood (2005) 106 (11): 148.

https://doi.org/10.1182/blood.V106.11.148.148

Published: 2005

Journal Articles

Deletion analysis of p16 INKa and p15 INKb in relapsed childhood acute lymphoblastic leukemia

Hagen Graf Einsiedel, Tillmann Taube, Reinhard Hartmann, Sven Wellmann, Georg Seifert, Günter Henze, Karl Seeger

Blood (2002) 99 (12): 4629–4631.

https://doi.org/10.1182/blood.V99.12.4629

Published: 2002

Journal Articles

Prognostic value of p16 INK4a gene deletions in pediatric acute lymphoblastic leukemia

Hagen Graf Einsiedel, Tillmann Taube, Reinhard Hartmann, Cornelia Eckert, Georg Seifert, Sven Wellmann, Günter Henze, Karl Seeger

Blood (2001) 97 (12): 4002–4004.

https://doi.org/10.1182/blood.V97.12.4002

Published: 2001

Journal Articles

TEL-AML1 Fusion in Relapsed Childhood Acute Lymphoblastic Leukemia

Karlheinz Seeger, Dirk Buchwald, Anita Peter, Tillmann Taube, Arend von Stackelberg, Gabriele Schmitt, Günter Henze

Blood (1999) 94 (1): 374–376.

https://doi.org/10.1182/blood.V94.1.374.413a48c_374_376

Published: 1999

NARROW

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML

Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP)

Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

Specific Inhibition of BCR-ABL Gene Expression in Acute Lymphoblastic Leukemia by Catalytic DNAzymes.

Deletion analysis of p16 INKa and p15 INKb in relapsed childhood acute lymphoblastic leukemia

Prognostic value of p16 INK4a gene deletions in pediatric acute lymphoblastic leukemia

TEL-AML1 Fusion in Relapsed Childhood Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only